<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108779</url>
  </required_header>
  <id_info>
    <org_study_id>QLF32004-101</org_study_id>
    <nct_id>NCT05108779</nct_id>
  </id_info>
  <brief_title>QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors</brief_title>
  <official_title>Phase Ia Clinical Study of Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of QLF32004 for Injection Monotherapy in Patients With Advanced Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety, tolerability, and recommended dose (RP2D) of QLF32004 in patients&#xD;
      with advanced malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 25, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-Emergent Adverse Event (TEAE)</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Event (SAE)</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Curve (AUC)</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Advanced Tumor</condition>
  <arm_group>
    <arm_group_label>QLF32004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QLF32004</intervention_name>
    <description>In the phase, five dose groups were proposed.The frequency of administration was once a week, and the treatment cycle was 3 weeks.</description>
    <arm_group_label>QLF32004</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18-75 years old .&#xD;
&#xD;
          2. Patients with advanced malignant solid tumors confirmed histologically or&#xD;
             cytologically have failed standard therapy, or have no standard therapy, or are not&#xD;
             eligible for standard therapy at this stage.&#xD;
&#xD;
          3. (dose escalation phase) At least one assessable tumor focus according to RECIST&#xD;
             1.1;(PK expansion phase) According to RECIST 1.1, there is at least one measurable&#xD;
             tumor lesion (a tumor lesion located in the area of previous radiotherapy or other&#xD;
             local regional treatment site is generally not considered measurable unless the lesion&#xD;
             shows definite progression or persists after 3 months of radiotherapy).&#xD;
&#xD;
          4. ECOG score 0-1.&#xD;
&#xD;
          5. Life expectancy ≥ 12 weeks.&#xD;
&#xD;
          6. Adequate organ function prior to the first use of the investigational drug (no use of&#xD;
             any blood components, cell growth factor, colony stimulating factor (G-CSF), rhTPO,&#xD;
             etc., or hepatoprotective therapy is permitted within 14 days prior to laboratory&#xD;
             examination);&#xD;
&#xD;
          7. Eligible fertile patients (male and female) must agree to use a reliable contraceptive&#xD;
             method (hormonal or barrier methods or abstinence, etc.) with their partner during the&#xD;
             trial and for 6 months after the last medication;Women of reproductive age must have a&#xD;
             negative blood pregnancy test within 7 days of their first use of the study drug;&#xD;
&#xD;
          8. Subjects shall give informed consent to this study before the test and voluntarily&#xD;
             sign a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy to the study drug or any excipients thereof; Or had a grade ≥3 allergic&#xD;
             reaction to protein drugs in the past.&#xD;
&#xD;
          2. Had received chemotherapy, radiotherapy, biotherapy, endocrine therapy, immunotherapy&#xD;
             and other anti-tumor treatments within 4 weeks prior to the first use of the study&#xD;
             drug.&#xD;
&#xD;
          3. Received any other investigational drug or treatment that is not on the market within&#xD;
             4 weeks prior to the first use of the investigational drug.&#xD;
&#xD;
          4. Use of live attenuated vaccine within 4 weeks prior to initial use of the study drug.&#xD;
&#xD;
          5. Received systemic glucocorticoid or other immunosuppressant treatment within 14 days&#xD;
             prior to initial use of the study drug.&#xD;
&#xD;
          6. Use of immunomodulatory drugs, including but not limited to thymosin.&#xD;
&#xD;
          7. Had major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks&#xD;
             prior to initial use of the study drug, or required elective surgery during the study&#xD;
             period.&#xD;
&#xD;
          8. Patients with cerebral parenchymal metastasis or meningeal metastasis with clinical&#xD;
             symptoms were judged by the investigator to be unsuitable for inclusion;&#xD;
&#xD;
          9. Patients with uncontrollable exudation (thorax, pericardium, abdominal cavity);&#xD;
&#xD;
         10. Have received immunotherapy and present with grade ≥ 3 irAE or grade ≥2&#xD;
             immune-associated myocarditis;&#xD;
&#xD;
         11. Adverse reactions of previous antitumor therapy have not recovered to CTCAE 5.0 rating&#xD;
             ≤1 (except toxicity without safety risk, such as hair loss, peripheral neurotoxicity&#xD;
             of grade 2, hypothyroidism stabilized by hormone replacement therapy, etc.);&#xD;
&#xD;
         12. Presence or history of any active autoimmune disease;Subjects with skin diseases that&#xD;
             do not require systemic treatment, such as vitiligo, psoriasis, hair loss, type I&#xD;
             diabetes, or asthma that has been completely resolved in childhood and does not&#xD;
             require any intervention as adults may be included;Asthma patients requiring medical&#xD;
             intervention with bronchodilators were excluded;&#xD;
&#xD;
         13. Patients with previous or current interstitial lung disease;&#xD;
&#xD;
         14. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency&#xD;
             syndrome (AIDS); Active hepatitis B, active hepatitis C;&#xD;
&#xD;
        16. Have a history of serious cardiovascular and cerebrovascular diseases; 17. Have active&#xD;
        infection and currently require intravenous anti-infection therapy; 18. Known history of&#xD;
        allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 19.&#xD;
        The patient is known to have a history of psychotropic drug abuse, alcoholism or drug&#xD;
        abuse;A clear past history of neurological or psychiatric disorders, including epilepsy or&#xD;
        dementia; 20. Patients with other serious physical or mental disorders or abnormal&#xD;
        laboratory tests that may increase the risk of study participation or interfere with study&#xD;
        results, and who are considered unsuitable for study participation by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

